Myocardial infarction occurs with a similar 24h pattern in the 4G/5G versions of plasminogen activator inhibitor-1

Chronobiology International

Volumn 26, Issue 4, 2009, Pages 637-652

  Bergheanu, Sandrin C ^a   Pons, Douwe ^a   Jukema, J Wouter ^a,b   Van Der Hoeven, Bas L ^a   Liem, Su San ^a   Vandenbroucke, Jan P ^a   Rosendaal, Frits R ^a   Le Cessie, Saskia ^a   Schalij, Martin J ^a   Van Der Bom, Johanna G ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Durrer Center for Cardiogenetic Research   (Netherlands)

Author keywords

Cardiovascular risk; Diurnal; Genotypes; Myocardial infarction; PAI 1

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; POISSON DISTRIBUTION; STATISTICAL MODEL;

CIRCADIAN RHYTHM; COHORT STUDIES; FEMALE; GENOTYPE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMORPHISM, GENETIC; RETROSPECTIVE STUDIES;

EID: 67651148051     PISSN: 07420528     EISSN: 15256073     Source Type: Journal    
DOI: 10.1080/07420520902925993     Document Type: Article

References (46)

1. Andreasen PA, Nielsen LS, Kristensen P, Grondahl-Hansen J, Skriver L, Dano K. (1986). Plasminogen activator inhibitor from human fibrosarcoma cells binds urokinase-type plasminogen activator, but not its proenzyme. J. Biol. Chem. 261:7644-7651.
2. Andreotti F, Kluft C. (1991). Circadian variation of fibrinolytic activity in blood. Chronobiol. Int. 8:336-351.
3. Angleton P, Chandler WL, Schmer G. (1989). Diurnal variation of tissue-type plasminogen activator and its rapid inhibitor (PAI-1). Circulation 79:101-106.
4. Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, Hochman JS, Krumholz HM, Kushner FG, Lamas GA, Mullany CJ, Ornato JP, Pearle DL, Sloan MA, Smith SC, Jr, Alpert JS, Anderson JL, Faxon DP, Fuster V, Gibbons RJ, Gregoratos G, Halperin JL, Hiratzka LF, Hunt SA, Jacobs AK. (2004). ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). Circulation 110:e82-e292.
5. Berry CN, Lunven C, Lechaire I, Girardot C, O'Connor SE. (1998). Antithrombotic activity of a monoclonal antibody inducing the substrate form of plasminogen activator inhibitor type 1 in rat models of venous and arterial thrombosis. Br. J. Pharmacol. 125:29-34.
6. Biemond BJ, Levi M, Coronel R, Janse MJ, ten Cate JW, Pannekoek H. (1995). Thrombolysis and reocclusion in experimental jugular vein and coronary artery thrombosis. Effects of a plasminogen activator inhibitor type 1-neutralizing monoclonal antibody. Circulation 91:1175-1181.
7. Booth NA, MacGregor IR, Hunter NR, Bennett B. (1987). Plasminogen activator inhibitor from human endothelial cells. Purification and partial characterization. Eur. J. Biochem. 165:595-600.
8. Booth NA, Robbie LA, Croll AM, Bennett B. (1992). Lysis of platelet-rich thrombi: the role of PAI-1. Ann. NY Acad. Sci. 667:70-80.
9. Cannon CP, McCabe CH, Stone PH, Schactman M, Thompson B, Theroux P, Gibson RS, Feldman T, Kleiman NS, Tofler GH, Muller JE, Chaitman BR, Braunwald E. (1997). Circadian variation in the onset of unstable angina and non-Q-wave acute myocardial infarction (the TIMI III Registry and TIMI IIIB). Am. J. Cardiol. 79:253-258.
10. Christian TF, Milavetz JJ, Miller TD, Clements IP, Holmes DR, Gibbons RJ. (1998). Prevalence of spontaneous reperfusion and associated myocardial salvage in patients with acute myocardial infarction. Am. Heart J. 135:421-427.
11. Cohen MC, Rohtla KM, Lavery CE, Muller JE, Mittleman MA. (1997). Meta-analysis of the morning excess of acute myocardial infarction and sudden cardiac death. Am. J. Cardiol. 79:1512-1516.
12. Coleman PL, Barouski PA, Gelehrter TD. (1982). The dexamethasone-induced inhibitor of fibrinolytic activity in hepatoma cells. A cellular product which specifically inhibits plasminogen activation. J. Biol. Chem. 257:4260-4264.
13. Davey SG, Ebrahim S. (2003). "Mendelian randomization": Can genetic epidemiology contribute to understanding environmental determinants of disease? Int. J. Epidemiol. 32:1-22.
14. Davey SG, Ebrahim S. (2005). What can mendelian randomisation tell us about modifiable behavioural and environmental exposures? BMJ. 330:1076-1079.
15. Dawson SJ, Wiman B, Hamsten A, Green F, Humphries S, Henney AM. (1993). The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J. Biol. Chem. 268:10739-10745.
16. Engel HJ, Lichtlen P. (1977). [Indications for a spontaneous thrombolysis in the human coronary system - coronary stenosis as a dynamic process?]. Verh. Dtsch. Ges. Inn. Med. 83:245-249 [in German].
17. Gils A, Declerck PJ. (2004). The structural basis for the pathophysiological relevance of PAI-I in cardiovascular diseases and the development of potential PAI-I inhibitors. Thromb. Haemost. 91:425-437.
18. Haus E. (2007). Chronobiology of hemostasis and inferences for the chronotherapy of coagulation disorders and thrombosis prevention. Adv. Drug. Deliv. Rev. 59:966-984.
19. Hermans PW, Hibberd ML, Booy R, Daramola O, Hazelzet JA, de Groot R, Levin M. (1999). 4G/5G promoter polymorphism in the plasminogen-activator- inhibitor-1 gene and outcome of meningococcal disease. Meningococcal Research Group. Lancet 354:556-560.
20. Hoekstra T, Geleijnse JM, Schouten EG, Kluft C. (2002). Diurnal variation in PAI-1 activity predominantly confined to the 4G-allele of the PAI-1 gene. Thromb. Haemost. 88:794-798.
21. Juhan-Vague I, Moerman B,DeCock F, Aillaud MF, Collen D. (1984). Plasma levels of a specific inhibitor of tissue-type plasminogen activator (and urokinase) in normal and pathological conditions. Thromb. Res. 33:523-530.
22. Kapiotis S, Jilma B, Quehenberger P, Ruzicka K, Handler S, Speiser W. (1997). Morning hypercoagulability and hypofibrinolysis. Diurnal variations in circulating activated factor VII, prothrombin fragment F1+2, and plasmin-plasmin inhibitor complex. Circulation 96:19-21.
23. Keavney B. (2002). Genetic epidemiological studies of coronary heart disease. Int. J. Epidemiol. 31:730-736.
24. Kruithof EK, Nicolosa G, Bachmann F. (1987). Plasminogen activator inhibitor 1: Development of a radioimmunoassay and observations on its plasma concentration during venous occlusion and after platelet aggregation. Blood 70:1645-1653.
25. Lee CW, Hong MK, Lee JH, Yang HS, Kim JJ, Park SW, Park SJ. (2001). Determinants and prognostic significance of spontaneous coronary recanalization in acute myocardial infarction. Am. J. Cardiol. 87:951-954.
26. Leiza JRG, de Llano JMA, Messa JBL, Lopez CA, Fernandez JA. (2007). New insights into the circadian rhythm of acute myocardial infarction in subgroups. Chronobiol. Int. 24:129-141.
27. Levi M, Biemond BJ, van Zonneveld AJ, ten Cate JW, Pannekoek H. (1992). Inhibition of plasminogen activator inhibitor-1 activity results in promotion of endogenous thrombolysis and inhibition of thrombus extension in models of experimental thrombosis. Circulation 85:305-312.
28. Liem SS, van der Hoeven BL, Oemrawsingh PV, Bax JJ, van der Bom JG, Bosch J, Viergever EP, van Rees C, Padmos I, Sedney MI, van Exel HJ, Verwey HF, Atsma DE, van der Velde ET, Jukema JW, van der Wall EE, Schalij MJ. (2007). MISSION!: Optimization of acute and chronic care for patients with acute myocardial infarction. Am. Heart J. 153:14.e1-14.e11.
29. Maemura K, de la Monte SM, Chin MT, Layne MD, Hsieh CM, Yet SF, Perrella MA, Lee ME. (2000). CLIF, a novel cycle-like factor, regulates the circadian oscillation of plasminogen activator inhibitor-1 gene expression. J. Biol. Chem. 275:36847-36851.
30. Marler JR, Price TR, Clark GL, Muller JE, Robertson T, Mohr JP, Hier DB, Wolf PA, Caplan LR, Foulkes MA. (1989). Morning increase in onset of ischemic stroke. Stroke 20:473-476.
31. Muller JE, Stone PH, Turi ZG, Rutherford JD, Czeisler CA, Parker C, Poole WK, Passamani E, Roberts R, Robertson T. (1985). Circadian variation in the frequency of onset of acute myocardial infarction. N. Engl. J. Med. 313:1315-1322.
32. Muller JE, Ludmer PL, Willich SN, Tofler GH, Aylmer G, Klangos I, Stone PH. (1987). Circadian variation in the frequency of sudden cardiac death. Circulation 75:131-138.
33. Nordenhem A, Leander K, Hallqvist J, de Faire U, Sten-Linder M, Wiman B. (2005). The complex between tPA and PAI-1: Risk factor for myocardial infarction as studied in the SHEEP project. Thromb. Res. 116:223-232.
34. Oehlert GW. (1992). A note on the delta method. Am. Stat. 46:27-29.
35. Ohkura N, Oishi K, Sakata T, Kadota K, Kasamatsu M, Fukushima N, Kurata A, Tamai Y, Shirai H, Atsumi G, Ishida N, Matsuda J, Horie S. (2007). Circadian variations in coagulation and fibrinolytic factors among four different strains of mice. Chronobiol. Int. 24:651-669.
36. Portaluppi F, Touitou Y, Smolenski MF. (2008). Ethical and methodological standards for laboratory and medical biological rhythm research. Chronobiol. Int. 25:999-1016.
37. Ridker PM, Vaughan PE, Stampfer MJ, Manson JE, Hennehens CH. (1993). Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet 341:1165-1168.
38. Rupin A, Martin F, Vallez MO, Bonhomme E, Verbeuren TJ. (2001). Inactivation of plasminogen activator inhibitor-1 accelerates thrombolysis of a platelet-rich thrombus in rat mesenteric arterioles. Thromb. Haemost. 86:1528-1531.
39. Sibbing D, von Beckerath O, von Beckerath N, Koch W, Mehilli J, Schwaiger M, Schomig A, Kastrati A. (2005). Plasminogen activator inhibitor-1 4G/5G polymorphism and efficacy of reperfusion therapy in acute myocardial infarction. Blood Coagul. Fibrinolysis 6:511-515.
40. Smolensky MH, Hermida RC, Portaluppi F, Haus E. (2007). Twenty-four-hour pattern of angina pectoris, myocardial infarction, and sudden cardiac death: Potential role of blood pressure, heart rate and rate-pressure product circadian rhythms. Biol. Rhythm Res. 38:205-216.
41. Swan HJ. (1989). Acute myocardial infarction: a failure of timely, spontaneous thrombolysis. J. Am. Coll. Cardiol. 13:1435-1437.
42. Van de Werf F, Ardissino D, Betriu A, Cokkinos DV, Falk E, Fox KA, Julian D, Lengyel M, Neumann FJ, Ruzyllo W, Thygesen C, Underwood SR, Vahanian A, Verheugt FW, Wijns W. (2003). Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Eur. Heart J. 24:28-66.
43. van der Bom JG, Bots ML, Haverkate F, Kluft C, Grobbee DE. (2003). The 4G5G polymorphism in the gene for PAI-1 and the circadian oscillation of plasma PAI-1. Blood 101:1841-1844.
44. van Giezen JJ, Wahlund G, Nerme AbrahamssonT. (1997). The Fab-fragment of a PAI-1 inhibiting antibody reduces thrombus size and restores blood flow in a rat model of arterial thrombosis. Thromb. Haemost. 77:964-969.
45. Wagner OF, Vetterlein M, Binder BR. (1986). Purification of an active plasminogen activator inhibitor immunologically related to the endothelial type plasminogen activator inhibitor from the conditioned media of a human melanoma cell line. J. Biol. Chem. 261:14474-14481.
46. Westendorp RG, Hottenga JJ, Slagboom PE. (1999). Variation in plasminogen-activator-inhibitor-1 gene and risk of meningococcal septic shock. Lancet 354:561-563.